Kura Oncology, Inc., a clinical-stage biopharmaceutical company headquartered in La Jolla, California, has released a series of regulatory filings on November 17, 2026, detailing recent adjustments to internal share ownership and institutional holdings. The filings, which include multiple Rule 144 submissions, indicate that several company officers have engaged in the sale of common shares through broker-dealer arrangements.
The transactions involve officers Brian Powl, Mollie Leoni, and Kathleen Ford, each of whom sold a portion of their restricted or performance stock units. These sales are characterized as routine corporate share-sale activity. Alongside these transactions, the company filed a Form 4/A to rectify prior ownership reporting, specifically providing clarification regarding indirect holdings maintained through a revocable trust.
In addition to the officer-led transactions, Kura Oncology submitted an amendment to a Schedule 13G/A. This filing was prompted by an update from Biotechnology Value Fund L P, which adjusted its shareholding status following a change of control event.
Despite these administrative updates and ownership disclosures, the filings do not indicate any significant market-impact events. Kura Oncology continues to focus its clinical development programs on addressing high unmet medical needs in oncology, specifically targeting lung, colorectal, thyroid, blood, and pancreatic cancers through the development of personalized therapeutics.
As of the market close on November 16, 2026, the company’s stock was priced at 7.49 USD on the Nasdaq exchange, with a market capitalization of approximately 651.42 million USD.




